Drug approval highlights for 2003.
D000212:Acyclovir / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy; D003879:Dermatologic Agents / Q000627:therapeutic use*; D017277:Drug Approval; D015914:Estrogen Replacement Therapy / Q000295:instrumentation; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy*; D005832:Genital Diseases, Male / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D008297:Male; D008333:Mandelic Acids / Q000627:therapeutic use; D012871:Skin Diseases / Q000188:drug therapy; D000077483:Valacyclovir; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016387:Women's Health
D002317:Cardiovascular Agents; D003879:Dermatologic Agents; D007155:Immunologic Factors; D008333:Mandelic Acids; D014633:Valine; C005419:oxybutynin; D000077483:Valacyclovir; D000212:Acyclovir